ADVERTISEMENT
2 /3 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Oncology

Synthekine launches with $82 million to pursue engineered cytokines

by Lisa M. Jarvis
September 19, 2020 | APPEARED IN VOLUME 98, ISSUE 36

 

Synthekine has launched with $82 million in its first formal funding round to engineer cytokines to make them safer and more effective as treatments for cancer and immune disease. The biotech firm, which already has two preclinical versions of the cytokine IL-2—a partial agonist and an orthogonal IL-2 ligand—was founded on technology developed by Stanford University structural biologist K. Christopher Garcia. A native form of IL-2 has been on the market for some time, but it doesn’t last long in the blood and can cause significant side effects.

X

Article:

This article has been sent to the following recipient:

Leave A Comment

*Required to comment